Skip to main content

Daclizumab Side Effects

Medically reviewed by Drugs.com. Last updated on Jun 1, 2023.

Applies to daclizumab: intravenous solution.

Warning

Intravenous route (Solution)

Only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe daclizumab, and they should have complete information requisite for the follow-up of the patient. Daclizumab should only be administered by healthcare personnel trained in the administration of the drug who have available adequate laboratory and supportive medical resources.

Serious side effects of Daclizumab

Along with its needed effects, daclizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking daclizumab:

Less common

Rare

Other side effects of Daclizumab

Some side effects of daclizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to daclizumab: intravenous solution, subcutaneous solution.

Cardiovascular

Common (1% to 10%): Lymphadenopathy, lymphadenitis[Ref]

Dermatologic

Very common (10% or more): Rash (i.e., erythematous rash, exfoliative rash, macular rash, maculopapular rash, papular rash, pruritic rash, rash, vesicular rash) (11%)

Common (1% to 10%): Dermatitis (i.e., allergic dermatitis, atopic dermatitis, bullous dermatitis, dermatitis, exfoliative dermatitis, seborrheic dermatitis, eczema, allergic dermatitis), folliculitis, acne, psoriasis, erythema, pruritus, dry skin

Uncommon (0.1% to 1%): Toxic skin eruption, eczema nummular[Ref]

Gastrointestinal

Common (1% to 10%): Tonsillitis, diarrhea

Frequency not reported: Colitis[Ref]

Hematologic

Common (1% to 10%): Anemia, lymphocyte count decreased[Ref]

Hypersensitivity

Frequency not reported: Anaphylaxis[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (25%), upper respiratory tract infection (17%)

Common (1% to 10%): Bronchitis, pneumonia, laryngitis, rhinitis[Ref]

Psychiatric

Common (1% to 10%): Depression[Ref]

Other

Common (1% to 10%): Oropharyngeal pain, pyrexia[Ref]

Hepatic

Common (1% to 10%): ALT increased, AST increased, liver function test abnormal, hepatic enzymes increased[Ref]

Immunologic

Common (1% to 10%): Influenza, viral infection[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Zinbryta (daclizumab). AbbVie US LLC. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.